Cancer is a major public health problem facing contemporary society. Notwithstanding considerable progress in medicine in recent decades, a cure for numerous cancer kinds continues to be unattainable. Thus, the pursuit of innovative therapeutic targets and methodologies remains paramount in medical research. The advancement of lipidomics has progressively revealed the essential roles of lipid metabolic pathways. Sphingosine kinase (SphK) and sphingosine-1-phosphate (S1P) are essential molecules in sphingolipid metabolism, significantly influencing physiological functions. Two isoforms of SPHK exist including SphK1 and SphK2, both of which exhibit significant expression levels within a spectrum of cancers. The involvement of SphK1 in carcinogenesis has been thoroughly documented, whereas the significance of SphK2 in cancer remains inadequately elucidated. This review retrospectively and extensively elucidates the expression and distribution of SphK2 in cancer, its methods of action, and advancements in inhibitor research, emphasizing the varied functions of the SphK2 in oncogenesis. The objective is to furnish novel insights for study and therapeutic applications concerning SphK2 in oncology.